Clinical Trials · NCT02559817

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation

Name: A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

TerminatedPhase 2Linaclotide

Phase: Phase 2
Recruitment status: Terminated
Sponsor: Forest Laboratories
Enrollment: 101
Start date: Nov 2015
Locations: 48 sites, United States, Canada
Primary endpoint: Change From Baseline in 4-week Overall Spontaneous Bowel Movement (SBM) Frequency Rate (SBMs/Week) During the Treatment Period

View Linaclotide compound reference